2026-07-242 min
Hexarelin: Adverse-Event Reporting and Evidence Boundaries
An evidence-led Hexarelin review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamEndocrine Safety
Safety signals and evidence gaps involving the GH and IGF-1 axis.
Open
2026-07-222 min
Hexarelin: Immunogenicity Questions and Evidence Boundaries
An evidence-led Hexarelin review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-07-222 min
Hexarelin: Safety Signal Review and Evidence Boundaries
An evidence-led Hexarelin review focused on safety signal review, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-07-182 min
GHRP-6: Adverse-Event Reporting and Evidence Boundaries
An evidence-led GHRP-6 review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-162 min
GHRP-6: Immunogenicity Questions and Evidence Boundaries
An evidence-led GHRP-6 review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Sports Integrity Desk2026-07-152 min
GHRP-6: Safety Signal Review and Evidence Boundaries
An evidence-led GHRP-6 review focused on safety signal review, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-07-122 min
Sermorelin: Adverse-Event Reporting and Evidence Boundaries
An evidence-led Sermorelin review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-07-092 min
Sermorelin: Immunogenicity Questions and Evidence Boundaries
An evidence-led Sermorelin review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team2026-07-092 min
Sermorelin: Safety Signal Review and Evidence Boundaries
An evidence-led Sermorelin review focused on safety signal review, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review Team